WNK1

Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers

Retrieved on: 
Thursday, April 18, 2024
FDA, University, Mouse, Biochemistry, Lab, Science Publishing Group, Unique, Identification, Research, Autophagy, Molecular biology, WNK1, Pediatrics, Plasma protein binding, Narendran, PV-10, Pharmaceutical industry

KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers.

Key Points: 
  • KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers.
  • The Narendran Lab provided preclinical proof-of-concept data supporting the efficacy of Provectus’s rose bengal in a panel of adult solid tumors.
  • The Lab identified that the Company’s rose bengal downregulated WNK1 and Wnt signaling.
  • In mice, the Narendran Lab also confirmed the clinical utility of Provectus’s rose bengal by intratumoral (aka intralesional) administration and demonstrated potential utility by oral administration.

Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia

Retrieved on: 
Wednesday, August 17, 2022
U.S. Securities and Exchange Commission, Narendran, Dermatology, Physiology, Molecular biology, Hematology, Cumming School of Medicine, Evaluation, Drug discovery, NIH, Forward-looking statement, Legislation, GLOBE, IL, SEC, Microbiology, Pharmacology, Medicine, National, Security (finance), Research, Science Publishing Group, Epson HX-20, Company, P.O, WNK1, Dimer, Virology, Safety, Doctor of Philosophy, OTCQB, Immunotherapy, Completeness, Ophthalmology, University, MD, HX, Biochemistry, Association, Pharmaceutical industry, Risk management, Pediatrics, Oncology

The Companys innovatively-assembled and proprietary rose bengal is the lead member of a class of small molecules called halogenated xanthenes.

Key Points: 
  • The Companys innovatively-assembled and proprietary rose bengal is the lead member of a class of small molecules called halogenated xanthenes.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes (HXs).
  • Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements.
  • Risks, uncertainties, and assumptions include those discussed in the Companys filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:

Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board

Retrieved on: 
Thursday, April 14, 2022
Head, Rhabdomyosarcoma, Biochemistry, Neck, Translational research, Ontario Cancer Institute, United, Princess Margaret Cancer Centre, Adult, Pediatrics, University, McMaster University, Coronavirus Scientific Advisory Board (Turkey), Research, Molecular biology, MD, Advanced Accelerator Applications, Ewing's sarcoma, Drug discovery, GLOBE, Science Publishing Group, Doctor of Philosophy, Hospital, Lysine, COG, Virology, Hematology, Company, RBS, Tufts University, Neuroblastoma, OTCQB, HSP, Odile Schweisguth, Coronavirus, Biology, Arizona State University, WNK1, Breast, Therapy, Ethics, Cancer, Medicine, Oncology

KNOXVILLE, TN, April 14, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Aru Narendran, MD, PhD to the Companys Scientific Advisory Board.

Key Points: 
  • KNOXVILLE, TN, April 14, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Aru Narendran, MD, PhD to the Companys Scientific Advisory Board.
  • Dr. Narendran received a PhD in neuroimmunology for his work in Dr. Steven Hoffmans laboratory at Arizona State University.
  • He is also a primary investigator and the director of biology for the Pediatric Oncology Experimental Therapeutics Consortium (POETIC).
  • Ed Pershing, Chair of Provectus Board of Directors, said, We are grateful to Dr. Narendran for accepting the invitation to join our Scientific Advisory Board, and deeply value his insights and continuous feedback.

Provectus Biopharmaceuticals Announces Presentation of Multiple Protein Kinase Signaling Targets, including WNK1, for PV-10® Immunotherapy at American Association for Cancer Research (AACR) 2022 Annual Meeting

Retrieved on: 
Monday, April 11, 2022
Virology, Company, National, Hematology, Glioblastoma, Neck, Cell death, Forward-looking statement, Immunotherapy, Legislation, WNK1, Adult, University of Calgary, Liver, Breast, AACR, SEC, Doctor of Philosophy, Research, Head, Immunogenic cell death, American Association, CT, Cancer, Dermatology, Tran, MD, Ophthalmology, Association, American Association for Cancer Research, Safety, NIH, University, ASCO, Cumming School of Medicine, GLOBE, Phosphorylation, Autophagy, Melanoma, Drug discovery, OTCQB, Microbiology, Lysine, Breast cancer, Patient, Large-cell lung carcinoma, Pharmaceutical industry, Vaccine, Medical imaging

The University of Calgary team subsequently investigated target validation and modulation of PV-10 treatment on protein kinase signaling and associated impacts on specific oncogenic pathways in these adult solid tumor cancers.

Key Points: 
  • The University of Calgary team subsequently investigated target validation and modulation of PV-10 treatment on protein kinase signaling and associated impacts on specific oncogenic pathways in these adult solid tumor cancers.
  • WNK1 potentially regulates important oncogenic pathways, including Wnt signaling by controlling -catenin levels.
  • We are grateful to Dr. Narendran and his University of Calgary team for their many discoveries related to PV-10 cancer treatment, including now identifying multiple, specific, actionable drug targets.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes.